GET DAILY SIGNALSARS Pharmaceuticals (SPRY) Posts Q3 Revenue Growth of 16% While Tightening Expenses
Key Takeaways
- Total revenue for the third quarter of 2026 rose 16% year over year to $37.7 million, including $33.4 million in U.S. net product revenue for neffy.
- The company reported a net loss of $0.36 per share, slightly wider than the consensus estimate of a $0.34 loss, while revenue came in below the roughly $42.7 million consensus.
- Selling, general and administrative (SG&A) expenses fell to $43.5 million, a more than 40% reduction from the first-half 2026 quarterly average.
- neffy U.S. market share reached about 5% overall and 9% in field-targeted accounts, with unique quarterly prescribers up 49% year over year.
- Management reaffirmed its path to cash flow breakeven by the end of 2027 and said it will provide full-year 2027 guidance with fourth-quarter results.
- For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available on Tickeron.
- To discover timely trade ideas and market opportunities, explore Trending AI Robots.
Putting the Quarter in Perspective
ARS Pharmaceuticals’ third-quarter 2026 results represent a meaningful checkpoint in the company’s shift to a more focused commercial approach. After the launch of its needle-free intranasal epinephrine treatment neffy, the firm initially leaned on broad consumer advertising. With new leadership in place, the emphasis has moved toward provider outreach and tighter cost controls. From what I see, this quarter offers a first look at whether that change is starting to deliver measurable progress on both the top and bottom lines. The update also highlights the ongoing effort to shift long-standing prescribing patterns in the epinephrine space, which will ultimately determine how quickly the company can reach the cash-flow breakeven target it has outlined.
Quarterly Results in Detail
Total revenue reached $37.7 million, a 16% increase from $32.5 million in the year-earlier period. That figure included $33.4 million in U.S. net product revenue from neffy, $2.6 million in ex-U.S. supply revenue, and $1.7 million in collaboration revenue. The net loss came in at $0.36 per share, compared with the $0.34 consensus estimate, while revenue fell short of the roughly $42.7 million Wall Street projection. On a positive note, the net loss narrowed to $35.6 million from $51.2 million a year ago.
Expense management stood out. Total operating expenses declined to $71.9 million from $95.1 million in the prior quarter, helped by an SG&A reduction to $43.5 million. R&D spending rose to $18.3 million, largely reflecting a one-time $12.5 million upfront payment tied to new intellectual-property rights. The company closed the quarter with $138.4 million in cash, cash equivalents, and short-term investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Views
Shares of SPRY fell after the release, reflecting disappointment that revenue missed expectations even as the company delivered on its cost-reduction commitments. The market appears focused on the gap between strong underlying demand growth and the slower conversion into reported revenue. Management pointed to inventory fluctuations as one factor, noting that end-user demand rose 42% year over year while net product revenue increased only about 7%. Sentiment remains measured, with investors balancing prescriber growth and rising market share against the revenue shortfall and a declining cash position.
What Comes Next
Management reiterated its expectation of reaching cash-flow breakeven by the end of 2027, supported by the lower expense base and anticipated revenue growth. Full-year 2027 guidance is expected alongside fourth-quarter results.
Several items deserve close attention. The commercial reset is projected to be largely complete operationally in the coming quarter, and the pace of market-share gains in field-targeted accounts will indicate whether the provider-focused strategy is gaining traction. Interim Phase 2b data for ARS-2 in chronic spontaneous urticaria remain on track for the first quarter of 2027, potentially expanding the addressable market. Finally, gross-to-net dynamics, payer coverage, and prior-authorization processes will determine how quickly reported revenue aligns with the demand trends the company is reporting.
Using AI Tools to Track Progress
I regularly turn to Tickeron’s AI Screener when evaluating companies like this one. The platform lets me filter by fundamentals, technical patterns, and industry trends in one place, which helps me quickly compare SPRY against peers and spot potential catalysts. It has become a useful part of my routine when reviewing quarterly updates and setting up alerts for key metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRY's Stochastic Oscillator remains in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +6.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 232 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 37 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for SPRY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.063) is normal, around the industry mean (2.904). P/E Ratio (-1.216) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement